---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-001193"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:22:17.255942+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CEO transition and positive FTX-6058 Phase 1b data; cash runway into late 2024

## Summary
- CEO Bryan Stuart departs; Robert Gould, former CEO/board member, appointed interim CEO effective Jan 3, 2023.
- FTX-6058 granted FDA Fast Track for SCD; Phase 1b shows HbF increases up to 9.5% at 6 mg, generally well tolerated.
- Plan to complete enrollment in Phase 3 REACH trial of losmapimod in FSHD during 2H 2023.
- Cash runway expected to fund operations into late 2024; next FTX-6058 data update expected in Q4 2023.
- Phase 1b enrollment ongoing in 12 mg cohort; dose-dependent HbF increase observed across adherent patients.

## SEC filing metadata
- accession: 0001193125-23-001193
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312523001193/0001193125-23-001193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312523001193/d445531d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-001193
- JSON: https://secwatch.observer/filing/0001193125-23-001193.json
- Plain text: https://secwatch.observer/filing/0001193125-23-001193.txt

## Key facts
- Executive change
  Bryan Stuart changed role as president, chief executive officer and Class II director at Fulcrum Therapeutics, Inc..
  - Action: transitioned
  - Role: president, chief executive officer and Class II director
  source text: On January 2, 2023, Bryan Stuart and Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed that he would transition from his role as president, chief executive officer and as Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312523001193/0001193125-23-001193-index.htm
- Executive change
  Robert J. Gould was appointed as Interim President and Chief Executive Officer at Fulcrum Therapeutics, Inc..
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: On January 3, 2023, the board of directors of Fulcrum, or the Board, appointed Robert J. Gould, former chief executive officer and president and current Class III director, as interim president and chief executive officer and as Fulcrum’s principal executive officer, effective January 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312523001193/0001193125-23-001193-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.